Human Genome reiterated at market outperform by JMP

JMP Securities analyst Charles C. Duncan reiterated Human Genome Sciences, Inc. at market outperform following a conference call with experts on systemic lupus erythematosus (SLE) who provided key insight into B cell targeted therapy and the mechanism of action of Lymphostat (different than that of Genentech's Rituxan). Shares of the Rockville, Md.-based biopharmaceutical company were down 21 cents, or 2.02%, at $10.19 on volume of 3,518,462 shares versus the three-month running average of 3,240,990 shares. (Nasdaq: HGSI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.